Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
SUVEN
Mr. Venkateswarlu Jasti M.Pharm. M.S. · Hyderabad, India
₹313.35
▲+6.53%SUVEN is a specialty pharmaceutical company experiencing significant volatility with today's surge amid negative financial metrics and low institutional ownership.
Exchange
NSI
Currency
INR
Day range
₹294.20 – ₹314.80
52-week range
₹124.11 – ₹371.00
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis40% confidence
Given the negative EPS, high debt/equity ratio, and lack of analyst consensus, the stock appears overvalued relative to fundamentals despite trading below its 52-week high.
15.5% below the 1-year high · trend up
Hedge-fund memo
Today
Significant price movement (+6.53%) on high volume, potentially driven by sector momentum or speculation
This week
No specific weekly trend data available, but stock is trading in the upper third of its recent range
This month
Stock has shown recovery from lower levels but remains below 52-week highs
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Neutral
1 headlines · 1 outlets · 7d
Racing TV·5d ago·irrelevant location name
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Earnings history unavailable for this symbol.
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| SUVEN | 88.54B | — | -78.80% | -3,435.00% | 3.60% |
| STAR | 97.70B | 17.58 | 20.03% | 8.56% | 11.20% |
| GRANULES | 206.65B | 30.96 | — |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Persistent negative profitability
Mitigation: Successful commercialization of pipeline products with higher margins
Regulatory setbacks for key products
Mitigation: Diversification of pipeline across multiple therapeutic areas
High debt-to-equity ratio
Mitigation: Improved cash flow generation and strategic debt reduction
Business intelligence
Competitive moat
Limited competitive moat currently, with potential moat development through successful R&D and proprietary formulations in specialty pharmaceuticals.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
FDA approvals for pipeline products
Financial results showing improvement in margins
Thesis builder
Bull case
Recovery in specialty pharmaceutical markets combined with successful pipeline launches could drive significant upside
Base case
Stabilization of current operations with gradual improvement in margins and profitability
Bear case
Continued losses, regulatory setbacks, or increased competition could lead to further decline
Time horizon
12-24 months
Est. CAGR
-10% to +15% (highly speculative given current losses)
Entry (qual.)
Wait for clear signs of profitability improvement and debt reduction
Exit (qual.)
If stock approaches 52-week high without fundamental improvement or if losses widen
Overall conviction 40%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how SUVEN fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain SUVEN for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Hold current position until profitability is demonstrated and debt metrics improve
Annual income statement, oldest → newest. Live via Yahoo.
| 17.56% |
| 22.00% |
| SPARC | 69.18B | 4.45 | 276.89% | 96.11% | 6,716.80% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹294.20
Resistance (day/52w high)
₹314.80
Volume
10,98,426
Trend
up
RSI (14)
38
MACD
bearish
MA cross
golden
50-day MA
₹290.27
200-day MA
₹200.25
vs 200-DMA
56.5%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.